Outcome of SARS-CoV-2 infection among patients with common variable immunodeficiency and a matched control group: A Danish nationwide cohort study

被引:14
作者
Katzenstein, Terese L. [1 ]
Rasmussen, Line D. [2 ]
Drabe, Camilla Helberg [1 ]
Larsen, Carsten Schade [3 ]
Hansen, Ann-Brit Eg [4 ,5 ]
Staerkind, Mette [6 ]
Knudsen, Lene Surland [7 ]
Hansen, Christian Holm [8 ]
Obel, Niels [1 ,5 ,8 ]
机构
[1] Copenhagen Univ Hosp, Dept Infect Dis, Rigshosp, Copenhagen, Denmark
[2] Odense Univ Hosp, Dept Infect Dis, Odense, Denmark
[3] Aarhus Univ Hosp, Dept Infect Dis, Aarhus, Denmark
[4] Copenhagen Univ Hosp Hvidovre, Dept Infect Dis, Copenhagen, Denmark
[5] Univ Copenhagen, Fac Hlth Sci, Copenhagen, Denmark
[6] Aalborg Univ Hosp, Dept Infect Dis, Aalborg, Denmark
[7] Zealand Univ Hosp, Dept Med, Roskilde, Denmark
[8] Statens Serum Inst, Dept Infect Dis Epidemiol & Prevent, Copenhagen, Denmark
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
关键词
severe adult respiratory coronavirus-2 (SARS-CoV-2); severe novel coronavirus 2019 (COVID-19); inborn errors of immunity (IEI); common variable immunodeficiency (CVID); clinical outcome; INBORN-ERRORS; COVID-19;
D O I
10.3389/fimmu.2022.994253
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The risk of severe adult respiratory coronavirus-2 (SARS-CoV-2) infection and the course of the infection among individuals with common variable immunodeficiency (CVID) relative to the general population have been a matter of debate. We conducted a Danish nationwide study comparing the timing of SARS-CoV-2 vaccination, the risk of first confirmed SARS-CoV-2 infection, re-infection, and the outcome of infection among individuals with CVID relative to an age- and gender matched control group. Cox regression was used to calculate incidence rate ratios. The CVID patients received SARS-CoV-2 vaccinations earlier than those included in the population control group. Even so, the risks of both first infection and re-infection were increased among the individuals with CVID. The CVID group also had increased risk for hospital contacts due to SARS-CoV-2 infection relative to the general population. However, reassuringly, the risk of mechanical ventilation and death did not differ between the groups, but the numbers were low in both groups, making the estimates uncertain. Though this is the largest study to investigate the risk of SARS-CoV-2 infections and outcomes hereof among individuals with CVID relative to the general population, we cannot rule out minor differences in severity, which might only be detectable with an even larger sample size.
引用
收藏
页数:10
相关论文
共 44 条
[1]   Immunodeficiency: A Protective Factor for COVID-19? [J].
AlShanableh, Zain ;
Haidous, Mohammad ;
Wong, Krista M. ;
Al-Saed, Mohamad ;
Altaqi, Basel .
CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (03)
[2]   Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines [J].
Andrews, Nick ;
Tessier, Elise ;
Stowe, Julia ;
Gower, Charlotte ;
Kirsebom, Freja ;
Simmons, Ruth ;
Gallagher, Eileen ;
Thelwall, Simon ;
Groves, Natalie ;
Dabrera, Gavin ;
Myers, Richard ;
Campbell, Colin N. J. ;
Amirthalingam, Gayatri ;
Edmunds, Matt ;
Zambon, Maria ;
Brown, Kevin ;
Hopkins, Susan ;
Chand, Meera ;
Ladhani, Shamez N. ;
Ramsay, Mary ;
Bernal, Jamie Lopez .
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (04) :340-350
[3]  
[Anonymous], STATA 14 STAT
[4]  
[Anonymous], VACCINATION CAALENDA
[5]  
[Anonymous], CLASSIFICATIONS SUND
[6]   Adverse COVID-19 outcomes in immune deficiencies: Inequality exists between subclasses [J].
Aydiner, Elif Karakoc ;
Eltan, Sevgi Bilgic ;
Babayeva, Royale ;
Aydiner, Omer ;
Kepenekli, Eda ;
Kolukisa, Burcu ;
Sefer, Asena Pinar ;
Gungoren, Ezgi Yalcin ;
Karabiber, Esra ;
Yucel, Esra Ozek ;
Ozdemir, Oner ;
Kiykim, Ayca ;
Artac, Hasibe ;
Yakici, Nalan ;
Yalcin, Koray ;
Cokugras, Haluk ;
Celkan, Tulin Tiraje ;
Orhan, Fazil ;
Yesilipek, Mehmet Akif ;
Baris, Safa ;
Ozen, Ahmet .
ALLERGY, 2022, 77 (01) :282-295
[7]   Insufficient type I IFN immunity underlies life-threatening COVID-19 pneumonia [J].
Bastard, Paul ;
Zhang, Qian ;
Cobat, Aurelie ;
Jouanguy, Emmanuelle ;
Zhang, Shen-Ying ;
Abel, Laurent ;
Casanova, Jean-Laurent .
COMPTES RENDUS BIOLOGIES, 2021, 344 (01) :19-25
[8]   Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial [J].
Bergman, Peter ;
Blennow, Ola ;
Hansson, Lotta ;
Mielke, Stephan ;
Nowak, Piotr ;
Chen, Puran ;
Soderdahl, Gunnar ;
Osterborg, Anders ;
Smith, C. I. Edvard ;
Wullimann, David ;
Vesterbacka, Jan ;
Lindgren, Gustaf ;
Blixt, Lisa ;
Friman, Gustav ;
Wahren-Borgstrom, Emilie ;
Nordlander, Anna ;
Gomez, Angelica Cuapio ;
Akber, Mira ;
Valentini, Davide ;
Norlin, Anna-Carin ;
Thalme, Anders ;
Bogdanovic, Gordana ;
Muschiol, Sandra ;
Nilsson, Peter ;
Hober, Sophia ;
Lore, Karin ;
Chen, Margaret Sallberg ;
Buggert, Marcus ;
Ljunggren, Hans-Gustaf ;
Ljungman, Per ;
Aleman, Soo .
EBIOMEDICINE, 2021, 74
[9]   Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies [J].
Bruel, Timothee ;
Hadjadj, Jerome ;
Maes, Piet ;
Planas, Delphine ;
Seve, Aymeric ;
Staropoli, Isabelle ;
Guivel-Benhassine, Florence ;
Porrot, Francoise ;
Bolland, William-Henry ;
Nguyen, Yann ;
Casadevall, Marion ;
Charre, Caroline ;
Pere, Helene ;
Veyer, David ;
Prot, Matthieu ;
Baidaliuk, Artem ;
Cuypers, Lize ;
Planchais, Cyril ;
Mouquet, Hugo ;
Baele, Guy ;
Mouthon, Luc ;
Hocqueloux, Laurent ;
Simon-Loriere, Etienne ;
Andre, Emmanuel ;
Terrier, Benjamin ;
Prazuck, Thierry ;
Schwartz, Olivier .
NATURE MEDICINE, 2022, 28 (06) :1297-+
[10]   Relative Vaccine Effectiveness of a Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine Booster Dose Against the Omicron Variant [J].
Butt, Adeel A. ;
Talisa, Victor B. ;
Shaikh, Obaid S. ;
Omer, Saad B. ;
Mayr, Florian B. .
CLINICAL INFECTIOUS DISEASES, 2022, 75 (12) :2161-2168